Loading
Instead of testing a drug in lab models first and hoping the results carry over, build the same models from trial participants and run both experiments in parallel to see how well the models predict.
Co-clinical trials generate patient-derived organoids or xenografts from enrolled participants and treat them with the trial regimen, with model results locked and blinded until the clinical readout. This produces a prospective, unbiased estimate of model predictive value, which the field currently lacks, and gives a resource for studying the responders and non-responders.
Shares Champions Oncology, Xilis, Patient-derived xenografts, Functional (ex vivo) drug testing.
Shares Champions Oncology, Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Xilis, Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived organoids to pick ADC payloads, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Xilis, Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids.